Genetic Testing for PML Risk Before Natalizumab Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict who is at risk of developing progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal opportunistic infection, despite known risk factors, necessitating a companion diagnostic to exclude high-risk individuals and ensure safe administration of treatments like natalizumab.
Innovation Solution
A genetic test is developed to identify genomic variations associated with a reduced risk of PML, allowing for the exclusion of high-risk individuals from immunosuppressive therapies, particularly natalizumab, by detecting specific genomic variations in a polynucleic acid sample.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive therapies like natalizumab are administered to treat autoimmune diseases, then treatment efficacy is improved, but the risk of developing PML increases
Solution Approach 1:
The patent applies preliminary action by performing genetic testing before administering immunosuppressive therapy to identify patients at high risk for PML. The test detects specific genomic variations (copy number variations) in genes such as CENPM, TNFRSF13C, and other markers that predict PML susceptibility. By screening patients beforehand, the system prevents high-risk individuals from receiving harmful treatments while allowing low-risk patients to benefit from effective therapy.
Solution Approach 2:
The patent introduces an intermediary diagnostic test between the patient and the immunosuppressive therapy. This companion diagnostic acts as a mediator that assesses PML risk through genetic analysis, providing a basis for informed treatment decisions. The test results serve as an intermediary factor that guides whether natalizumab or similar therapies should be administered, thereby resolving the contradiction between treatment benefit and PML risk.
2Object-affected harmful factors
If genetic testing is performed to identify PML risk, then patient safety is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex genetic analysis into specific, targeted assessments of known PML-risk genomic variations. Rather than performing comprehensive whole-genome sequencing, the diagnostic focuses on detecting copy number variations in specific genes and genetic markers previously identified as PML risk factors. This segmented approach maintains patient safety while reducing diagnostic complexity.
Solution Approach 2:
The patent changes the diagnostic parameter from broad, complex genetic profiling to specific detection of copy number variations in predetermined genes. By focusing on quantifiable genetic markers (presence or absence of specific CNVs in genes like CENPM, TNFRSF13C, etc.), the test simplifies the diagnostic process while maintaining high predictive value for PML risk assessment.
3Measurement precision
If comprehensive risk assessment methods are used, then prediction accuracy is improved, but testing time and resources increase
Solution Approach 1:
The patent applies preliminary action by pre-identifying and validating specific genetic markers associated with PML risk before developing the diagnostic test. Research has already established which copy number variations in which genes predict PML susceptibility. This preliminary research phase allows the clinical test to focus only on detecting these known markers, achieving high prediction accuracy without requiring time-consuming comprehensive genomic analysis.
Solution Approach 2:
The patent extracts and isolates the specific genetic components that contribute to PML risk from the complex genome. By focusing only on detecting copy number variations in specific genes (CENPM, TNFRSF13C, and other validated markers) rather than analyzing the entire genome, the test achieves high prediction accuracy while minimizing testing time and resources. Irrelevant genetic information is excluded from the diagnostic process.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.